Generic competition · all medicines · read 12 November 2026
Is there a generic of Metoprolol Tartrate, and who makes it?
Metoprolol Tartrate appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 15 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 9.7 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Metoprolol Tartrate appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 15 generic makers listed as marketed across them.
- 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came 9.7 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Tablet, Oral
Four or more generic makers listed
Brand listed as marketed: Lopressor. 8 generic makers with 28 generic products listed as marketed; the first generic approval is dated 21 December 1993.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Adaptis Pharma Private Ltd | 27 April 1995 | 2 |
| Sun Pharmaceutical Industries Inc | 10 December 1996 | 2 |
| Mylan Pharmaceuticals Inc | 16 January 2004 | 5 |
| Aurobindo Pharma Ltd | 11 September 2007 | 5 |
| Ipca Laboratories Ltd | 17 June 2008 | 3 |
| Alembic Pharmaceuticals Ltd | 28 May 2013 | 3 |
| Rubicon Research Ltd | 28 October 2014 | 5 |
| Sciegen Pharmaceuticals Inc | 5 February 2020 | 3 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Injectable, Injection
Four or more generic makers listed
Every brand product here is listed as discontinued. 7 generic makers with 7 generic products listed as marketed; the first generic approval is dated 21 December 1993.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Hikma Pharmaceuticals Usa Inc | 7 July 2003 | 1 |
| Hikma Farmaceutica (Portugal) Sa | 30 May 2007 | 1 |
| Sandoz Inc | 2 October 2007 | 1 |
| Hospira Inc | 29 April 2008 | 1 |
| Fresenius Kabi Usa Llc | 25 October 2010 | 1 |
| Baxter Healthcare Corp | 29 April 2013 | 1 |
| Gland Pharma Ltd | 27 August 2014 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Solution, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Lopressor. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.